|
1
|
Van Meir EG, Hadjipanayis CG, Norden AD,
Shu HK, Wen PY and Olson JJ: Exciting new advances in
neuro-oncology: the avenue to a cure for malignant glioma. CA
Cancer J Clin. 60:166–193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wiedemeyer R, Brennan C, Heffernan TP,
Xiao Y, Mahoney J, Protopopov A, Zheng H, Bignell G, Furnari F,
Cavenee WK, et al: Feedback circuit among INK4 tumor suppressors
constrains human glioblastoma development. Cancer Cell. 13:355–364.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Coras R, Hölsken A, Seufert S, Hauke J,
Eyüpoglu IY, Reichel M, Tränkle C, Siebzehnrübl FA, Buslei R,
Blümcke I and Hahnen E: The peroxisome proliferator-activated
receptor-γ agonist troglitazone inhibits transforming growth
factor-β-mediated glioma cell migration and brain invasion. Mol
Cancer Ther. 6:1745–1754. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu Z, He B, He J and Mao X: Upregulation
of miR-153 promotes cell proliferation via downregulation of the
PTEN tumor suppressor gene in human prostate cancer. Prostate.
73:596–604. 2013. View Article : Google Scholar
|
|
6
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kent OA and Mendell JT: A small piece in
the cancer puzzle: microRNAs as tumor suppressors and oncogenes.
Oncogene. 25:6188–6196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu Z, Han Y, Li Y, Li X, Sun T, Chen G,
Huang Y, Zhou Y and Du Z: MiR-218-5p inhibits the stem cell
properties and invasive ability of the
A2B5+CD133− subgroup of human glioma stem
cells. 35:869–877. 2016.
|
|
9
|
Sand M, Skrygan M, Sand D, Georgas D,
Gambichler T, Hahn SA, Altmeyer P and Bechara FG: Comparative
microarray analysis of microRNA expression profiles in primary
cutaneous malignant melanoma, cutaneous malignant melanoma
metastases, and benign melanocytic nevi. Cell Tissue Res.
351:85–98. 2013. View Article : Google Scholar
|
|
10
|
Lai KW, Koh KX, Loh M, Tada K, Subramaniam
MM, Lim XY, Vaithilingam A, Salto-Tellez M, Iacopetta B, Ito Y, et
al: Singapore Gastric Cancer Consortium: MicroRNA-130b regulates
the tumour suppressor RUNX3 in gastric cancer. Eur J Cancer.
46:1456–1463. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Scheffer AR, Holdenrieder S, Kristiansen
G, von Ruecker A, Müller SC and Ellinger J: Circulating microRNAs
in serum:novel biomarkers for patients with bladder cancer? World J
Urol. 32:353–358. 2014. View Article : Google Scholar
|
|
12
|
Colangelo T, Fucci A, Votino C, Sabatino
L, Pancione M, Laudanna C, Binaschi M, Bigioni M, Maggi CA, Parente
D, et al: MicroRNA-130b promotes tumor development and is
associated with poor prognosis in colorectal cancer. Neoplasia.
15:1218–1231. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu X, Weng L, Li X, Guo C, Pal SK, Jin JM,
Li Y, Nelson RA, Mu B, Onami SH, et al: Identification of a
4-microRNA signature for clear cell renal cell carcinoma metastasis
and prognosis. PLoS One. 7:e356612012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Malzkorn B, Wolter M, Liesenberg F,
Grzendowski M, Stühler K, Meyer HE and Reifenberger G:
Identification and functional characterization of microRNAs
involved in the malignant progression of gliomas. Brain Pathol.
20:539–550. 2010. View Article : Google Scholar
|
|
15
|
Yip L, Kelly L, Shuai Y, Armstrong MJ,
Nikiforov YE, Carty SE and Nikiforova MN: MicroRNA signature
distinguishes the degree of aggressiveness of papillary thyroid
carcinoma. Ann Surg Oncol. 18:2035–2041. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dong P, Karaayvaz M, Jia N, Kaneuchi M,
Hamada J, Watari H, Sudo S, Ju J and Sakuragi N: Mutant p53
gain-of-function induces epithelial-mesenchymal transition through
modulation of the miR-130b-ZEB1 axis. Oncogene. 32:3286–3295. 2013.
View Article : Google Scholar :
|
|
17
|
Leone V, Langella C, D'Angelo D, Mussnich
P, Wierinckx A, Terracciano L, Raverot G, Lachuer J, Rotondi S,
Jaffrain-Rea ML, et al: Mir-23b and miR-130b expression is
downregulated in pituitary adenomas. Mol Cell Endocrinol. 390:1–7.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao G, Zhang JG, Shi Y, Qin Q, Liu Y,
Wang B, Tian K, Deng SC, Li X, Zhu S, et al: MiR-130b is a
prognostic marker and inhibits cell proliferation and invasion in
pancreatic cancer through targeting STAT3. PLoS One. 8:e738032013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Walbert T and Chasteen K: Palliative and
supportive care for glioma patients. Cancer Treat Res. 163:171–184.
2015. View Article : Google Scholar
|
|
20
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun C, Li N, Zhou B, Yang Z, Ding D, Weng
D, Meng L, Wang S, Zhou J, Ma D and Chen G: miR-222 is upregulated
in epithelial ovarian cancer and promotes cell proliferation by
downregulating P27(kip1). Oncol Lett. 6:507–512. 2013.PubMed/NCBI
|
|
22
|
Liu Y, Yan W, Zhang W, Chen L, You G, Bao
Z, Wang Y, Wang H, Kang C and Jiang T: MiR-218 reverses high
invasiveness of glioblastoma cells by targeting the oncogenic
transcription factor LEF1. Oncol Rep. 28:1013–1021. 2012.PubMed/NCBI
|
|
23
|
Stefani G and Slack FJ: Small non-coding
RNAs in animal development. Nat Rev Mol Cell Biol. 9:219–230. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Esquela-Kerscher A and Slack FJ: Oncomirs
– microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu T, Cao R, Li S, Fu M, Ren L, Chen W,
Zhu H, Zhan Q and Shi R: MiR-130b plays an oncogenic role by
repressing PTEN expression in esophageal squamous cell carcinoma
cells. BMC Cancer. 15:292015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang C, Cai J, Wang Q, Tang H, Cao J, Wu L
and Wang Z: Epigenetic silencing of miR-130b in ovarian cancer
promotes the development of multidrug resistance by targeting
colony-stimulating factor 1. Gynecol Oncol. 124:325–334. 2012.
View Article : Google Scholar
|
|
28
|
Tu K, Zheng X, Dou C, Li C, Yang W, Yao Y
and Liu Q: MicroRNA-130b promotes cell aggressiveness by inhibiting
peroxisome proliferator-activated receptor gamma in human
hepatocellular carcinoma. Int J Mol Sci. 15:20486–20499. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kliewer SA, Xu HE, Lambert MH and Willson
TM: Peroxisome proliferator-activated receptors: from genes to
physiology. Recent Prog Horm Res. 56:239–263. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pestereva E, Kanakasabai S and Bright JJ:
PPARγ agonists regulate the expression of stemness and
differentiation genes in brain tumour stem cells. Br J Cancer.
106:1702–1712. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Michalik L, Desvergne B and Wahli W:
Peroxisome-proliferator-activated receptors and cancers: complex
stories. Nat Rev Cancer. 4:61–70. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Drori S, Girnun GD, Tou L, Szwaya JD,
Mueller E, Xia K, Shivdasani RA and Spiegelman BM: Hic-5 regulates
an epithelial program mediated by PPARgamma. Genes Dev. 19:362–375.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang MH, Zhong XY, Lin CL, Xie YK, Jia JP,
Li SM and Mi C: Expression of peroxisome proliferator-activated
receptor gamma in glioma. Nan Fang Yi Ke Da Xue Xue Bao.
28:444–446. 2008.In Chinese. PubMed/NCBI
|
|
34
|
Papi A, Tatenhorst L, Terwel D, Hermes M,
Kummer MP, Orlandi M and Heneka MT: PPARgamma and RXRgamma ligands
act synergistically as potent antineoplastic agents in vitro and in
vivo glioma models. J Neurochem. 109:1779–1790. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jansson EA, Are A, Greicius G, Kuo IC,
Kelly D, Arulampalam V and Pettersson S: The Wnt/β-catenin
signaling pathway targets PPARgamma activity in colon cancer cells.
Proc Natl Acad Sci USA. 102:1460–1465. 2005. View Article : Google Scholar
|
|
36
|
Wan Z, Shi W, Shao B, Shi J, Shen A, Ma Y,
Chen J and Lan Q: Peroxisome proliferator-activated receptor γ
agonist pioglitazone inhibits β-catenin-mediated glioma cell growth
and invasion. Mol Cell Biochem. 349:1–10. 2011. View Article : Google Scholar : PubMed/NCBI
|
